- Entry
- $2.29
- Final
- $2.76 +20.5%
- Target
- —
- Score
- +1.00
After the latest launch of TrumpRx it quickly became obvious that it is just a nice design, which relates on GoodRX technology. For details read the FT Artikel, the announcement of Pfizer, and the Investor News of GDRX. Which was feared to be the GDRX killer will now give them extra traffic. So why only a small pop yesterday which retreated already? Is the business or the balancesheet flawed? No, even with a decining legacy business in the higher single …
— ORIGINAL POST ·
TrumpRx is a front for GDRX but nobody cares about the stock
· r/wallstreetbets
· Feb 6, 2026